The Relief Therapeutics (OTCMKTS:RLFTF) stock has carried on from where it left off yesterday and has jumped by 2% so far this morning.
This morning the stock jumped after it emerged that the company’s partner NRx Pharmaceuticals submitted an application for Emergency Use Authorization to the United States Food and Drug Administration for the permission of deploying aviptadil in the treatment of COVID 19 patients. That is a major development for Relief Therapeutics, since aviptadil was created by it and its lead compound.
Although it is true that a large number of people have been vaccinated, there is still the need for effective therapeutic options for people who still contract the disease. Hence, products like aviptadil are important in the larger scheme of things. The company is optimistic about the potential of the product when it comes to effectively treating COVID 19 patients. Investors could do well to keep an eye on the developments over the coming days.
At the time of writing, RLFTF stock is up by 2% to $0.245. The stock has seen a total volume of 1.05 million shares, compared to its average volume of 7.27 million shares.